ClinicalTrials.govpublic full text
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
crohn disease (cd), crohn disease, tnf inhibitor, infliximab, adalimumab, upadacitinib, dose intensification, dual-target therapy, multicenter randomized controlled trial, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 863179
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.